<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="177806">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00780481</url>
  </required_header>
  <id_info>
    <org_study_id>061160</org_study_id>
    <nct_id>NCT00780481</nct_id>
  </id_info>
  <brief_title>Characterization of Brachial Arterial t-PA Release, Endothelial Function, Obesity and Inflammation</brief_title>
  <acronym>P1A3B</acronym>
  <official_title>Characterization of Brachial Arterial t-PA Release, Vasodilator Function, and Vascular Compliance and Correlation With Fibrinolytic Balance, Oxidative Stress, and Inflammation Measures (SCCOR Project 1 Aim 3B)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      T-PA release is impaired in obese subjects. In order to have a better mechanistic
      understanding of t-PA release, we will compare t-PA release to Flow Mediated Vasodilation,
      Radial Artery Tonometry, and other markers of endothelial function and oxidative stress.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of enrollment due to strict inclusion/exclusion criteria. Bradykinin shortage
  </why_stopped>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak t-PA release</measure>
    <time_frame>Single Study day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak FMD</measure>
    <time_frame>Single Study Day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radial Artery Elasticity</measure>
    <time_frame>Single Study Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid levels, PAI-1 levels, CRP levels, F2 Isoprostanes and other biomarkers of inflammation and obesity.</measure>
    <time_frame>Single Study Day</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Bradykinin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will have flow mediated vasodilation and radial artery tonometry performed. They will then receive 0, 10, 20, 40 ng/100cc/min of intrabrachial bradykinin. Strain gauge plethysmography and blood sampling at each dose will be done to evaluate t-PA release. Blood will also be drawn for other biomarkers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bradykinin</intervention_name>
    <description>Intrabrachial - 0, 10, 20, 40 ng/100cc/min over 5 minutes at each dose.</description>
    <arm_group_label>Bradykinin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Adults 18 years and greater

          2. Healthy

        Exclusion criteria:

          1. PVC &lt; 30

          2. Hypertensive subjects on ACE inhibitors

          3. Pregnant or nursing mothers

          4. Diabetic with HbA1C &gt; 7.5 or stigmata of end organ damage (neuropathy, retinopathy,
             nephropathy, cardiomyopathy)

          5. Cholesterol &gt; 30 mg/dL above NCEP accepted level based on cardiac risk.

          6. Triglycerides &gt; 200

          7. Previously diagnosed obstructive coronary artery disease, myocardial infarction or
             left ventricular dysfunction (with or without a history of congestive heart failure)

          8. Renal insufficiency (Creatinine ≥ 1.5 mg/dl)

          9. History of cerebrovascular disease

         10. Any chronic inflammatory disease (rheumatologic, inflammatory bowel disease, etc)

         11. Uncontrolled Stage 2 Hypertension (160/100 mmHg), or end organ damage due to
             hypertension (left ventricular hypertrophy, atrial fibrillation, hematuria, renal
             insufficiency, prior cerebrovascular disease).

         12. Angiotensin converting enzyme inhibitor use

         13. Coagulopathy (INR ≥ 1.5, PTT ≥ 1.5 x control)

         14. Other chronic medical illnesses at the discretion of the investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James AS Muldowney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 14, 2016</lastchanged_date>
  <firstreceived_date>October 24, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>James Muldowney</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Endothelial Function</keyword>
  <keyword>Fibrinolytic Balance</keyword>
  <keyword>Baseline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bradykinin</mesh_term>
    <mesh_term>Kininogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
